key: cord-0759012-cet1svz2 authors: Uwishema, Olivier; Chalhoub, Elie; Torbati, Tania; David, Success Chekwube; Khoury, Carlo; Ribeiro, Lucas Loiola Ponte Albuquerque; Nasrallah, Yves; Bekele, Bezawit Kassahun; Onyeaka, Helen title: Rift Valley fever during the COVID‐19 pandemic in Africa: A double burden for Africa's healthcare system date: 2022-01-06 journal: Health Sci Rep DOI: 10.1002/hsr2.468 sha: 36990e998173c4b708464df34318558d856369f5 doc_id: 759012 cord_uid: cet1svz2 A new rising incidence of Rift Valley fever (RVF) among livestock and humans in the African continent during the COVID‐19 pandemic has become of increasing concern. We analyzed the different ways COVID‐19 has contributed to the increase in RVF cases and how it has impacted the interventions allocated to the disease by comparing it with the status of the disease before the pandemic. There is enough evidence to conclude that the COVID‐19 pandemic has impacted the efforts being taken to prevent outbreaks of RVF. Therefore, with no definitive treatment in place and inadequate preventive measures and disease control, RVF may potentially lead to a future epidemic unless addressed urgently. Less than a century ago, a new virus causing fever was discovered in the Rift Valley region of Kenya, thereby naming the new organism the Rift Valley fever virus (RVFV). 1 Although more than 90 years have passed, the virus' real impact and treatment are still misunderstood. 1 The situation led the World Health Organization (WHO) and many African nations to prioritize the pathogen with respect to assigning it more urgent research and development. 2, 3 RVF is a disease that attacks mainly domesticated ruminants and sometimes humans in sub-Saharan Africa, particularly the East and South regions, Egypt, Saudi Arabia, and Yemen ( Figure 1 ). 4 while facing the first ever major outbreak of RVF. It was not until the South African outbreak in 1974 that the first ever human death due to RVF was recorded. 7 Consequently, it became clear that RVF posed an economic threat to communities that rely on the meat, milk, and trade of affected livestock. 8 The most suitable approach to prevent the critical dangers of RVF is via immunizing animals with one of a variety of vaccinations. 1 Because multiple doses of immunization are required, inactivated or killed vaccines are not appropriate for regular animal field vaccination. The Smithburn vaccine, a modified live vaccine, is Africa's oldest and most used vaccine for preventing RVF. This vaccine conveniently requires only one dose; however, it has been linked to birth abnormalities and demonstrated low effectiveness. 4 Several potential vaccinations are currently being researched and tested. In laboratory studies of domesticated animals, the liveattenuated vaccine MP-12 has shown promise, but further investigation is needed before the vaccine can be deployed in the field. Of note, South Africa has approved and started using the live-attenuated Clone 13 vaccine. Also, alternative vaccines based on molecular recombinant constructions are now being developed. 4 Although frequent outbreaks still exist in the 21st century, vaccination has played a major role in reducing the severity of these epidemics. 1 A new outbreak of RVF has recently emerged in Africa, with 109 confirmed and suspected cases in Madagascar according to the WHO 9 and 4 deaths in Uganda. 10 Unfortunately, this outbreak appeared during the SARS-CoV-2 global pandemic, which made the situation worse. RVFV and SARS-coV-2 both share some common clinical features: for example, in their early course, the two viruses cause flu-like, febrile diseases that may continue undetected due to the nonspecific symptoms. Also, the incubation period of both viruses is 3-6 days. 1 Such commonalities between the two viruses have led to delayed diagnosis and consequently postponed treatment and increased hospitalization. On the other hand, the major difference between RVFV and SARS-CoV-2 is the route of transmission: while the latter is transmitted through respiratory droplets, there have not been any confirmed cases of person-to-person transmission of RVFV 4 (Table 1) . To date, there is no approved human vaccine against RVFV, although the virus is listed as a priority pathogen by the WHO because of its high potential to cause an outbreak and lack of effective precautionary measures. 1 The preoccupation of healthcare workers in fighting COVID-19 is slowing down research on a vaccine against RVFV, deeming the current is declared: closing livestock markets and butcheries, imposing controls on movement, and banning raw milk. 22 The impact of COVID-19 on the economy and coexisting RVF outbreaks have presented a drastic challenge to both the economy and the fragile healthcare system of African nations. 23 The difficulties of concurrently addressing COVID-19 and RVF in Africa are associated with certain shortcomings such as insufficient resources and technical capacity, thereby impeding efforts against an appropriate response. Also, the lack of protective equipment, which when available is assigned to COVID-19 relief efforts, has resulted in morbidity and mortality, as evidenced in some occupational groups. 24 There is no known treatment for RVF, but it may be managed and prevented with the distribution and administration of vaccines. However, the supply for RVFV livestock immunizations has been insufficient and cannot protect populations on a large scale. 6 As such, immediate actions need to be taken, such as increasing surveillance and educating the public on the health risks of RVFV infection, to promote the safety of Africa's civilians. The COVID-19 pandemic serves as a pivotal moment that provides an unprecedented awareness of infectious diseases, highlighting essential yet unmet needs as well as multiple challenges in global healthcare and countries' health systems. For instance, the lack of research and development of evidence-based practices in public health, universal health coverage, accessibility, awareness, and trustworthy information for the public have all contributed to healthcare limitations from a global standpoint. As a result, the increased risk of highly infectious disease outbreaks, such as RVF during the COVID-19 pandemic, is significant and expresses a concern among specialists. 25 RVF is a relevant disease affecting public health in the Arabian Peninsula, sub-Saharan Africa, Egypt, and Madagascar, yet Asian countries have recently shown worrying signs of increased cases and transmission of zoonotic infections. 26 For example, in the last few years, Korea has observed the presence of seroprevalence in local animals with no human cases yet to be registered, and China was the first to report human cases with infection related to RVFV imported from Angola. 2, 27 The spread of RVFV to new countries alongside recurrent outbreaks in Africa and the overlapping COVID-19 pandemic has set alarm bells ringing for a hazardous rise in disease transmission and possible damages to global health and economy. 26 Because of RVF's regional distribution in the past, very few studies have been conducted regarding its manifestations, specificities, infection ratio, and potential illness in humans. As such, there is a crucial demand for evidence-based data, with an emphasis on epidemiological studies and protocols in multiple regions as well as further studies on RVF in the context of the SARS-CoV-2 global pandemic. 1, 25, 26 A One Health approach is highly favorable with regard to RVF response, as it underscores the development of a working group to explore and identify possible risk factors for infection and disease progression to severe presentation. Also, it is imperative to raise awareness about RVF among the governments and civil society, with health policy campaigns to increase education and subsequently prevent outbreaks. 1 In this context, we recommend adopting an intersectional approach between different disciplines, including partnerships joining experts on animal and environmental health with local, national, and international healthcare workers in at-risk regions. 1, 25 An interdisciplinary approach is imperative to minimize damages to public health, society, and economy, to prevent infections in animals and humans, and to contribute to a sustainable recovery from the unprecedented global health crisis that is the COVID-19 pandemic. 28 None. We have not received any funding for this study. No conflict of interest declared. Efficacy Trials of Rift Valley Fever Vaccines and Therapeutics Guidance on Clinical Trial Design Meeting Report 2 RVF Vaccine and Treatment Evaluation Joint Risk Assessment (JRA) accomplished for effective control of zoonotic diseases in South Sudan. WHO j Regional Office for Africa Priority diseases. CEPI. 2021. Accessed Rift Valley Fever. CDC. 2020. Accessed Rift Valley fever virus targets the maternal-foetal interface in ovine and human placentas The next pandemic: Rift Valley fever? www.gavi.org. 2021 Rift Valley fever in Kenya: history of epizootics and identification of vulnerable districts The Story of the Rift Valley Fever Virus Vaccine j One Health j CDC. www.cdc.gov Madagascar reports more than one hundred total Rift Valley fever cases. Outbreak News Today Rift Valley fever kills 4 in Kiruhura Bird flu outbreak amidst COVID-19 pandemic in South Africa: efforts and challenges at hand Fighting COVID-19 at the expense of malaria in Africa: the consequences and policy options Ebola outbreak amid COVID-19 in the Republic of Guinea: priorities for achieving control Measles crisis in Africa amidst the COVID-19 pandemic: delayed measles vaccine administration may cause a measles outbreak in Africa Viral infections amidst COVID-19 in Africa: implications and recommendations Dengue fever outbreak in Cook Island: a rising concern, efforts, challenges and future recommendations Epidemic of plague amidst COVID-19 in Madagascar: efforts, challenges, and recommendations Lassa fever amidst the COVID-19 pandemic in Africa: a rising concern, efforts, challenges and future recommendations The rising incidence of African swine fever during the COVID-19 pandemic in Africa: efforts, challenges and recommendations Threats and outbreaks of cholera in Africa amidst COVID-19 pandemic: a double burden on Africa's health systems The syndemic burden of HIV/-AIDS in Africa amidst the COVID-19 pandemic Response to Rift Valley fever in Tanzania: challenges and opportunities The health and economic burden of the coronavirus in sub-Saharan Africa Rift Valley fever in the horn of Africa: challenges and opportunities Rift Valley fever and COVID-19 outbreak in Kenya: a double whammy Prevalence of human Rift Valley fever virus as a bio-threat in Asian countries after COVID-19 lockdown Serological surveillance studies confirm the Rift Valley fever virus free status in South Korea Object: FAO and IGAD Are Joining Forces against Rift Valley Fever Rift Valley fever during the COVID-19 pandemic in Africa: A double burden for Africa's healthcare system